Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–35.
Article
CAS
Google Scholar
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091–103.
Article
CAS
Google Scholar
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797–804.
Article
CAS
Google Scholar
Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29.
Article
Google Scholar
Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23(30):7565–73.
Article
CAS
Google Scholar
Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23(4):712–9.
Article
CAS
Google Scholar
Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105(12):4576–82.
Article
CAS
Google Scholar
Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352(5):441–9.
Article
CAS
Google Scholar
Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, et al. Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the in-111 ((111)in)/yttrium 90 ((90)Y) Ibritumomab Tiuxetan (Zevalin((R))) Theranostic pair in patients with lymphoma at Myeloablative dose levels. Cancers. 2021;13(11).
Cameron PJ, Klemp PF, Martindale AA, Turner JH. Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy. Nucl Med Commun. 1999;20(7):609–15.
Article
CAS
Google Scholar
Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al. Efficacy and safety of high-specific-activity (131)I-MIBG therapy in patients with advanced Pheochromocytoma or Paraganglioma. J Nucl Med. 2019;60(5):623–30.
Article
CAS
Google Scholar
Garske-Roman U, Sandstrom M, Fross Baron K, Lundin L, Hellman P, Welin S, et al. Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970–88.
Article
CAS
Google Scholar
Sundlov A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830-40.
Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, et al. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728–42.
Article
Google Scholar
Menda Y, Madsen MT, O'Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, et al. (90)Y-DOTATOC dosimetry-based personalized peptide receptor radionuclide therapy. J Nucl Med. 2018;59(11):1692–8.
Article
CAS
Google Scholar
Bushnell DL, Bodeker KL, O'Dorisio TM, Madsen MT, Menda Y, Graves S, et al. Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for personalized treatment of selected patients with neuroendocrine tumors. J Nucl Med. 2021;62(9):1274–7.
Article
CAS
Google Scholar
Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14(7):1974–81.
Article
CAS
Google Scholar
Goldsmith SJ. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med. 2010;40(2):122–35.
Article
Google Scholar
Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, et al. A phase 1 trial of (90)Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplant. 2017;52(10):1372–7.
Article
CAS
Google Scholar
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.
Article
CAS
Google Scholar
GE Healthcare. Metastron (strontium-89 chloride injection) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020134s012lbl.pdf. Revised December 2013. Accessed 11 Nov 2022.
Lantheus Medical Imaging, Inc. Quadramet (samarium-153 lexidronam injection) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020570s008lbl.pdf. Revised September 2017. Accessed 11 Nov 2022.
Bayer HealthCare Pharmaceuticals Inc. Xofigo (radium-223 dichloride injection) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf. Revised December 2019. Accessed 11 Nov 2022.
Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.
Article
Google Scholar
Progenics Pharmaceuticals, Inc. Azedra (iobenguane I 131 injection) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209607s000lbl.pdf. Revised July 2018. Accessed 11 Nov 2022.
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.
Article
CAS
Google Scholar
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–30.
Article
CAS
Google Scholar
Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319–25.
Article
CAS
Google Scholar
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1752–63.
Article
CAS
Google Scholar
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar AE, et al. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J Clin Oncol. 2021;39(15_suppl):4112.
Article
Google Scholar
Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847–56.
Article
CAS
Google Scholar
Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, et al. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT. EJNMMI Phys. 2018;5(1):25.
Article
Google Scholar
Del Prete M, Buteau FA, Beauregard JM. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44(9):1490–500.
Article
Google Scholar
Benua RSLRD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. Front Thyroidology New York: Plenum Medical. 1986;2:1317–21.
Google Scholar
Pacilio M, Conte M, Frantellizzi V, De Feo MS, Pisani AR, Marongiu A, et al. Personalized dosimetry in the context of radioiodine therapy for differentiated thyroid Cancer. Diagnostics. 2022;12(7):1763. https://pubmed.ncbi.nlm.nih.gov/35885666/.
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate Cancer: correlations between Pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23.
Article
CAS
Google Scholar
Hanscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after Endoradiotherapy with (177)Lu-DOTATATE/DOTATOC by a single measurement after 4 days. J Nucl Med. 2018;59(1):75–81.
Article
Google Scholar
Madsen MT, Menda Y, O'Dorisio TM, O'Dorisio MS. Technical Note: Single time point dose estimate for exponential clearance. Med Phys. 2018;45(5):2318–24.
Article
Google Scholar
Hou X, Brosch J, Uribe C, Desy A, Boning G, Beauregard JM, et al. Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. J Nucl Med. 2021;62(7):1006–11.
Article
CAS
Google Scholar
Sistani G, Sutherland DEK, Mujoomdar A, Wiseman DP, Khatami A, Tsvetkova E, et al. Efficacy of (177)Lu-Dotatate induction and maintenance therapy of various types of neuroendocrine tumors: a phase II registry study. Curr Oncol. 2020;28(1):115–27.
Article
Google Scholar